Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term carboplatin. Found 40 abstracts

no pagination
Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1339-49.
Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK, Maxwell GL. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study. Gynecologic Oncology. 2011 Sep;122(3):521-6.   PMCID: *
Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research. 2010 Apr;16(8):2450-7.   PMCID: not NIH funded
Hu W, Ding WJ, Yang HH, Shao MH, Wang BY, Wang JH, Wu SF, Wu SX, Jin LH, Ma CC. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiotherapy and Oncology. 2009 Dec;93(3):488-91.
Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic Oncology. 2008 Aug;110(2):140-5.
Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology. 2007 Jun;60(1):81-9.
Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY. 2006 Sep;102(3):432-9.
Bookman MA, McMeekin DS, Fracasso PM. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 2006 Nov;103(2):473-8.
Engstrom PF, Langer CJ. The Balducci article reviewed. ONCOLOGY-NEW YORK. 2006 Feb;20(2):144-+.
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansar R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2006 May;24(13):2038-43.
Langer CJ. Treatment of stage I-III non-small-cell lung cancer in the elderly - The Gridelli/Maione/Rossi article reviewed. ONCOLOGY-NEW YORK. 2006 Apr;20(4):385-+.
Masters GA, Li SG, Dowlati A, Madajewicz S, Langer C, Schiller J, Johnson D. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group Study (E1501). JOURNAL OF THORACIC ONCOLOGY. 2006 Sep;1(7):673-8.
Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. International Journal of Gynecological Cancer. 2005 Nov 03;15:212-20.
Langer CJ, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, Wilson JF. Patterns of care survey (PCS) in lung cancer: how well does current US practice with chemotherapy in the non-metastatic setting follow the literature?. Lung Cancer. 2005 Apr;48(1):93-102.
Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. Journal of Clinical Oncology. 2005 Apr;23(10):2145-54.
Ozols RF. NICE guidelines for ovarian cancer: Recommendations versus standard care. Cancer Investigation. 2004 Jan;22 (5):815-7.
Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG0 182-ICON5. International Journal of Gynecological Cancer. 2003 Nov;13(6):735-40.
Guo P, Li SL, Gallo JM. Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. 2003 Jan;783(1):43-52.
Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. New England Journal of Medicine. 2000 Apr 13;342(15):1069-76.
Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology. 1998 Aug;25(4):2-10.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term carboplatin

carboplatin paclitaxel chemotherapy randomized-trial cisplatin ovarian cancer Oncology phase-iii trial cyclophosphamide CARCINOMA adjuvant chemotherapy mutations neoadjuvant induction TRIAL chemoradiation EXPRESSION cancer radiation-therapy STAGE-III phase-iii quality-of-life leukemia group-b cell lung-cancer intraperitoneal cisplatin GYNECOLOGIC-ONCOLOGY-GROUP gynecologic-oncology-group PACLITAXEL rescue drug hypersensitivity older patients gemcitabine EPIDERMAL-GROWTH-FACTOR bone-marrow transplantation high-dose carboplatin CETUXIMAB concurrent chemotherapy phase-ii aggressive surgery chemoradiotherapy Microscopic residual stage-iii resistant fallopian-tube 2006 i ds-v24-p2396 CARBOPLATIN KeyWords Plus: PHASE-III comparing cisplatin pharmacokinetics phase-i-platinum(ii)-paclitaxel-rat phase I oncology remission CHEMOTHERAPY ifosfamide CISPLATIN vincristine single-agent southwest-oncology-group PROGRESSION INFUSION 5-fluorouracil topotecan CYCLOPHOSPHAMIDE standard therapy platinum pegylated liposomal doxorubicin Chemoradiotherapy concurrent pathway SURVIVAL primary peritoneal cancer patterns of care survey weekly paclitaxel intensification surgery doublets early stage EOC hypersensitivity reactions DOUBLETS VEGFR-2 NSCLC CELL LUNG-CANCER lymphoma phase-ii trial phase II exisulind 1st-line treatment Nasopharyngeal carcinoma p-32 stage-ii support Locally advanced neck hyperfractionated radiation-therapy lung cancer novel agent hypersensitivity AGENT erlotinib primary angiogenesis therapy WOMEN doxorubicin gefitinib survival consolidation therapy tumors age thiotepa selection prognostic-factors epithelial ovarian VITRO MONOCLONAL-ANTIBODIES thoracic radiotherapy critique resection ENDOTHELIAL GROWTH-FACTOR recurrent epithelial ovarian carcinoma phase II trial radiotherapy follow-up advanced-stage ovarian docetaxel etoposide INTERGROUP TRIAL non-small cell lung cancer regimen sequential impact vinblastine pharmacokinetics RECEPTOR clinical-trials GEFITINIB Epithelial ovarian cancer braf gene second-look Obstetrics & Gynecology head surgical cytoreduction neoplasm trial tyrosine kinase inhibitor BEVACIZUMAB TYROSINE KINASE INHIBITOR trial debulking surgery
Last updated on Friday, January 03, 2020